Fields of Interest: apoptosis, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo2L), non-small cell lung cancer, carcinogenesis, autoimmune diseases, systemic lupus erythematosus

Tenev T, Bohmer SA, Kaufmann R, Frese S, Bittorf T, Beckers T, Bohmer FD
Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells.
Eur J Cell Biol. 2000 Apr;79(4):261-71.
Abstract

Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA
Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
J Thorac Cardiovasc Surg. 2002 Jan;123(1):168-74.
Abstract

Frese S, Schaper M, Kuster JR, Miescher D, Jaattela M, Buehler T, Schmid RA
Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage.
J Thorac Cardiovasc Surg. 2003 Sep;126(3):748-54.
Abstract

Kuester JR, Frese S, Stein RM, Roth T, Beshay M, Schmid RA
Treatment of primary spontaneous pneumothorax in Switzerland: results of a survey.
Interact Cardiovasc Thorac Surg. 2006 Apr;5(2):139-44. Epub 2006 Jan 13.
Abstract

Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, Schmid RA
PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.
Oncogene. 2003 Aug 21;22(35):5427-35.
Abstract

Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA
Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Cancer Res. 2006 Jun 1;66(11):5867-74.
Abstract

Pirnia F, Frese S, Gloor B, Hotz MA, Luethi A, Gugger M, Betticher DC, Borner MM
Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples.
Anticancer Res. 2006 May-Jun;26(3A):1765-72.
Abstract

Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D, Kassahn D, Torgler R, Mueller C, Schneider P, Brunner T
TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality.
J Clin Invest. 2006 Sep;116(9):2493-9.
Abstract

Plock J, Frese S, Keogh A, Bisch-Knaden S, Ayuni E, Corazza N, Weikert C, Jakob S, Erni D, Dufour JF, Brunner T, Candinas D, Stroka D
Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver.
J Hepatol. 2007 Oct;47(4):538-45. Epub 2007 Jun 4.
Abstract

Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okumura K, Aoyama T, Frese S, Ikeda H, Haynes NM, Cretney E, Yagita H, Sueyoshi N, Sato N, Nakanuma Y, Smyth MJ, Okumura K
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10895-900. Epub 2008 Jul 30.
Abstract

Frese S, Schuller A, Frese-Schaper M, Gugger M, Schmid RA
Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Anticancer Res. 2009 Aug;29(8):2905-11.
Abstract

Frese-Schaper M, Zbaeren J, Gugger M, Monestier M, Frese S
Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
J Immunol. 2010 Feb 15;184(4):2175-82. Epub 2010 Jan 18.
Abstract

Frese-Schaper M, Schardt JA, Sakai T, Carboni GL, Schmid RA, Frese S
Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5.
FEBS Lett. 2010 Jul 2;584(13):2867-71. Epub 2010 May 7.
Abstract